

[[6] 高明明,刘云芝,杨新春. 血脂康对心肌梗死患者的疗效及安全性研究 [J]. 中国心血管杂志, 2007, 12 (3): 182-184.

[[7] 那静涛,汤伯赞,于晓艳. 步长脑心通对 248 例心肌梗死二级预防的临床观察 [J]. 哈尔滨医药, 2011, 31 (3): 162-163.

Cohort Study on the Endpoint Events in 238 Myocardial Infarction Patients

DAI Guohua¹, ZHAO Chen², LONG Fengxi², LOU Hao², WANG Fang²

(1. Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong Province, 250011; 2. Shandong University of Traditional Chinese Medicine)

ABSTRACT Objective To investigate the related factors of endpoint events in myocardial infarction (MI) patient. **Methods** Hospitalized cases with first diagnosis of acute myocardial infarction from January 2008 to December 2012 in Affiliated Hospital of Shandong University of Traditional Chinese Medicine were collected. In the period of hospitalization and follow-ups, cohort study questionnaire for the Chinese medicine hospital was applied to record general information, usage of traditional Chinese medicine (TCM), types and time of the endpoint events, number of occurrence and evidence. Logistic regression analysis was used to analyze the correlation of TCM intervention intensity, age, gender, complications, drug usage and other indicators with the occurrence of endpoint events. **Results** Totally 238 MI patients were included and 152 patients had complete follow-ups. In hospitalization, the top three endpoint events in MI patients were acute heart failure (AHF, 18.49%), cardiac death (CD, 16.81%) and cardiogenic shock (CGS, 14.45%). In the follow-ups, the top three endpoint events were cardiac readmission (30.19%), CD (25.16%) and AHF (13.84%). In hospitalization, TCM intervention intensity (OR = 7.753) and age (OR = 1.230) were related factors of CD, while age (OR = 1.055) was a related factor of AHF and age (OR = 1.072) was that of CGS. In the follow-ups, antithrombotic medication (OR = 2.831), cholesterol-lowering medication (OR = 2.696), pathoglycemia (OR = 2.734), TCM intervention intensity (OR = 1.528) and age (OR = 1.053) were related factors of CD, while pathoglycemia (OR = 2.793), TCM intervention intensity (OR = 1.587) and age (OR = 1.054) were that of AHF and age (OR = 1.074) was that of severe arrhythmia. **Conclusion** TCM intervention, age, complications were related factors to the endpoint events in MI patients and TCM intervention could effectively prevent CD and AHF in follow-ups.

Keywords myocardial infarction; endpoint event; TCM therapy; cohort study

(收稿日期: 2014-05-16; 修回日期: 2014-08-09)

编辑: 崔京艳

中药上市后大品种二次研发高层培训班通知

由世界中医药学会联合会国际合作部、《世界中医药》杂志社联合主办的国家中医药继续教育项目“中药上市后大品种二次研发高层培训班”拟于 2015 年 5 月在北京举办。由北京华盛国际医药信息交流中心、北京漫青国际医药科技有限公司承办,由中国中医科学院中药所药物安全性评价中心主任、博士生导师、世界中联中药新型给药系统专业委员会会长、药品管理与中药知识产权保护委员会主任委员叶祖光首席研究员、中国中医科学院临床医院研究所常务副所长谢雁鸣研究员、中国中医科学院西苑医院翁维良首席研究员以及上海中医药大学(原国家药审中心中医临床部部长)张磊教授等主讲。

1. 授课内容: 中成药大品种上市后再评价; 循证医学在中药临床再评价中应用; 中药注射剂的风险评估与管理; 基于真实世界的临床研究; 中药 IV 期临床研究与再评价; 基于临床的中药新药的研发; 中药上市后合理用药的研究与评价; 中药上市后安全性再评价的研究; 中成药进入医保相关政策解读; 中药新药临床研究的进展等。2. 培训对象: 各医药企业(厂)、保健品公司(厂)董事长、总经理、科研、市场、媒体筹划、产品开发(研发)、公共事务部、学术等部门负责人和各大院校(所)医院科研管理及研究人员等。3. 培训时间与学费: 学期 4 天(报到 1 天,授课 3 天),每位学员学费 2960 元/人,海外学员 3980 元/人(含午餐、场地费、讲议费、专家课时费、证书费、纪念品等)。报名时交个人身份证复印件,2 寸免冠照片 2 张。须提前报名: 国内报名费 200 元/人(含在学费中); 海外学员报名费 400 元/人(含学费中,可将报名费汇到指定帐户或邮局,并提前 1 个月通知入学时间、地点,提前 2 个月报名者优惠 10%)。4. 学满课时待遇: 按国家中医药继续教育之规定,学满课时颁发国家中英文对照结业证书,并授予 I 类学分 12 学分证书。参加学习班学员的投稿达到《世界中医药》杂志登刊标准者优先发表。5. 培训地点与住宿: 中国中医科学院内(北京市东直门内南小街 16 号)。6. 汇款方式: 邮局汇款收款人: 北京华盛国际医药信息交流中心,地址: 北京市朝阳区小营路 19 号财富嘉园 A 座 301 室; 银行汇款户名: 北京华盛国际医药信息交流中心,开户银行: 兴业银行知春路支行,帐号: 321180100100043563。7. 联系方式: 北京市朝阳区小营路 19 号财富嘉园 A 座 301 室,世界中医药学会联合会国际合作部。邮编: 100101。联系人: 王炳岐、徐晖、赵和爱、景晓杨(13901318403),邓爱英(13051608026)。邮箱: 13901318403@139.com。电话/传真: (010) 58239066、(010) 58239055。叶恒(13501288390)。邮箱: hy0388@163.com。